Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology33Abbreviations: MIBG, m-iodobenzylguanidine; MGBG, methylglyoxal bis(guanylhydrazone); MIBA, m-iodobenzylamine; BG, benzylguanidine; NE, norepinephrine; GBG, glyoxal bis(guanylhydrazone); EGBG, ethylglyoxal bis(guanylhydrazone); MGBCP, methylglyoxal bis(cyclopentylamidinohydrazone); ODC, ornithine decarboxylase; and SAMDC, S-adenosylmethionine decarboxylase.

Ekelund, Sara; Nygren, Peter; Larsson, Rolf

doi:10.1016/s0006-2952(01)00570-6

Cited by 58 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…69 Certain synthetic molecules as meta-iodobencylguanidine (MIBG) interact with this transporter in a similar way that the natural epinephrine. 70 We have found that the attachment of a specific MIBG derivative, meta-aminobencylguanidine (MABG) through a cross-linker based on polyethylene glycol of 2000 Da of molecular weight (PEG 2000 ) enhances the nanoparticle uptake by the NB cells in more than four times improving the cytotoxic capacity of the nanocarrier against this disease.…”

Section: Active Targetingmentioning

confidence: 99%

Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution

et al. 2016

View full text Add to dashboard Cite

Since 2001, when our research group proposed for the first time MCM-41 as drug release system, the scientific community is devoting growing interest to mesoporous silica nanoparticles (MSNs) for their revolutionary potential in nanomedicine. Among the diverse pathologies that can be treated with MSNs, cancer has received increasing attention. MSNs can be loaded with large amounts of therapeutic cargoes and once intravenously administrated preferentially accumulate at solid tumours via enhanced permeation and retention (EPR) effect. Herein we report the recent developments achieved by our research group as a pioneer into this field, highlighting: the design of sophisticated MSNs as stimuli-responsive drug delivery systems to release the entrapped cargo upon exposure to a given stimulus while preventing the premature release of highly cytotoxic drugs before reaching the target; transporting non-toxic prodrugs and the enzyme responsible for its conversion into cytotoxic agents into the same MSN; improving the selectivity and cellular uptake by cancer cell by active targeting of MSNs; increasing the penetration of MSNs within the tumour mass, which is one of the major challenges in the use of NPs to treat solid tumours.

show abstract

Section: Active Targetingmentioning

confidence: 99%

Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Modified m IBG ( 127 I-MoM-Boc) was synthesized from 1,3-bis( tert -butoxycarbonyl) guanidine ( N , N ′-di-Boc-guanidine) and 1,4-bis(bromomethyl)-2-iodobenzene. The modification was made at C-4 of m IBG to maintain the affinity binding to NET, 42–45 and characterized using 1 H, 13 C nuclear magnetic resonance (NMR) and mass spectrometry. Then the 127 I-MoM-Boc was conjugated to carboxylated PEG-GNPs; deprotection was subsequently performed to obtain 127 I-MoM-PEG-GNPs.…”

Section: Introductionmentioning

confidence: 99%

A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, guanidine-containing derivatives have been shown to have antitumor, 40–42 antibiotic, 43,44 and antiviral properties. 45 Regarding the biological target, the guanidine group is frequent in both enzyme inhibitors 46,47 and ligands for different receptors and ion channels.…”

Section: Introductionmentioning

confidence: 99%

Solid-Phase Synthesis of a Library of Amphipatic Hydantoins. Discovery of New Hits for TRPV1 Blockade

et al. 2011

View full text Add to dashboard Cite

Some heterocyclic systems, called privileged scaffolds, appear frequently in bioactive products and marketed drugs. The combination of a recognized privileged scaffold (hydantoin) and a functional group with high incidence in bioactive molecules (guanidine) guided the design of a library of amphipatic compounds, which allowed to discover novel TRPV1 ion channel blockers. The library was synthesized by parallel solid-phase synthesis from an orthogonally protected resin-bound Lys-Lys skeleton. Key steps of the synthetic procedure were the construction of the hydantoin ring, by reaction of the N-terminal amino group with N,N-disuccinimidyl carbonate (DSC) and subsequent base-induced cyclization, and the guanidinylation of the C-terminal Lys side-chain after removal of the Alloc protecting-group. The preliminary biological studies have allowed the identification of some of the key structural features directing the blockage of capsaicin-induced Ca2+ influx through TRPV1 channels, particularly, the strong preference showed for highly lipophilic acyl groups and substituted guanidine moieties. Active compounds based on this new pharmacophoric scaffold that display in vitro and in vivo inhibitory activity

show abstract

Cited by 58 publications

References 61 publications

Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution

Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution

A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment

Solid-Phase Synthesis of a Library of Amphipatic Hydantoins. Discovery of New Hits for TRPV1 Blockade

Contact Info

Product

Resources

About